Astellas Pharma Inc. has been consistently making news in the biotech space with several crucial developments and announcements. Some of our noteworthy takeaways involve Astellas' various partnerships, such as collaborating with the Korean Institute of Startup and Entrepreneurship Development and Mitsubishi Research Institute to fuel biotech innovation and support pharma startups. An important legal issue arose with an Astellas employee being sentenced to three and a half years in a Chinese prison for espionage, which has been acknowledged by the company. The firm's strategic growth path is further evidenced by the launch of their new research hub for Korean biotech startups and the opening of a life sciences center in Cambridge, Massachusetts. Additionally, Astellas' fiscal performance has been quite encouraging with the company beating earnings expectations and reporting significant US sales of Izervay. Several product launches and regulatory approvals such as VYLOY™ and IZERVAY™ have also been announced. However, FDA has issued a complete response letter for Avacincaptad pegol (Izervay), raising new questions in stomach cancer and moving their pipeline forward.
Astellas Pharma Inc. News Analytics from Mon, 11 Oct 2021 07:00:00 GMT to Sat, 19 Jul 2025 09:32:35 GMT -
Rating 6
- Innovation 8
- Information 7
- Rumor -3
